| Diagnosis and Treatment of Multidrug/Rifampicin-Resistant Tuberculosis |
|
Saerom Kim1, Jeongha Mok1,2 |
1Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea
2Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea |
| 다제내성/리팜핀내성결핵의 진단과 치료 |
|
김새롬1, 목정하1,2 |
1부산대학교병원 호흡기내과
2부산대학교 의과대학 내과학교실 |
Correspondence:
Jeongha Mok, Tel: +82-51-240-7889, Fax: +82-51-240-8677, Email: mokgamokga@gmail.com
|
|
Received: 26 July 2025 • Revised: 4 October 2025 • Accepted: 19 November 2025 |
|
|
| Abstract |
|
To rapidly diagnose multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB), all individuals suspected of having tuberculosis should undergo the Xpert MTB/RIF assay or an equivalent test capable of simultaneously detecting Mycobacterium tuberculosis and rifampicin resistance. Upon confirmation of rifampicin resistance, treatment for MDR/RR-TB should be initiated promptly, with preference given to shorter treatment regimens, such as BPaLM, MDR-END, or BPaL. Medications included in each regimen should be administered at the recommended dosages and for the entire treatment duration. Careful monitoring and management of potential adverse effects, including bone marrow suppression, peripheral neuropathy, optic neuritis, and QT interval prolongation are essential. The advent of shorter regimens has made MDR/RR-TB treatment more convenient and accessible for many patients. However, to further improve treatment outcomes and reduce the prevalence of MDR/RR-TB in Korea, comprehensive patient-centered management should be integrated across all stages of diagnosis and treatment. |
| Key Words:
Tuberculosis, multidrug-resistant; Rifampin; Tuberculosis |
| 주제어:
다제내성결핵; 리팜핀; 결핵 |
|
PDF Links
Full text via DOI
Download Citation
